Pfizer, Astellas say Xtandi drug combo reduces risk of metastasis, death in prostate cancer by 58%
Pfizer and Astellas touted more detailed data over the weekend on their drug Xtandi in a type of prostate cancer, which the companies say show …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
